Menu
© 2019 All rights reserved.
YBhg. Dato’ Sri Mohd Mokhtar was appointed to the Board on 25 January 2019.
YBhg. Dato’ Sri Mohd Mokhtar holds a degree in Bachelor of Law (Hons), a Masters of Business Administration and a Certificate of Legal Practice
YBhg. Dato’ Sri Mohd Mokhtar had served the Royal Malaysia Police 3rd July 1977 – 22nd May 2018. Positions held during his service were as follows:
Aged 35, Malaysian
Executive Director
Group Chief Executive Officer
Ms. Nadiah Wan, aged 34, was appointed as Chief Executive Officer of Thomson Hospitals Sdn Bhd and Group Chief Corporate Officer of TMC Life Sciences Berhad on 19 June 2017.
Prior to joining Thomson Hospitals Sdn Bhd and the Company, Ms. Nadiah Wan worked in Sunway Medical Centre as Chief Operating Officer (Clinical Services) after being promoted from Director of Business Development and Corporate Communications in October 2016. She started her career at The Boston Consulting Group in 2007 as an Associate Consultant before joining Sunway Group as Manager, Strategy and Corporate Development in 2010.
Ms. Nadiah Wan holds MSc Public Health Nutrition degree qualification from the London School of Hygiene and Tropical Medicine, UK and an AB cum Laude in Biochemical Sciences from Harvard College. She also serves as an Interviewer for Harvard College admissions and is an Exco member of the Harvard Club of Malaysia.
Ms. Nadiah Wan does not hold any directorship in other public companies and listed issuer in Malaysia. She has no family relationship with any Director and/or major shareholder of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. Also, she has no conflict of interest with the Company.
Aged 64, Malaysian
Executive Director
Member of Nomination Committee
Mr. Barry Kan was appointed to the Board on 2 June 2015. He is a veteran of almost 30 years in the automotive industry with rich and vast experience in managing various illustrious global brands during his career with renowned regional dealership, Wearnes Automotive, headquartered in Singapore. Prior to that, he was with the Port Authority of Singapore for 7 years.
As General Manager at Malayan Motors (a division then of Wearnes Automotive Pte Ltd), his portfolio included the Rolls-Royce, Bentley, Jaguar and Volvo Trucks franchises in Singapore. He was also responsible for the introduction of some of the brands into new territories such as Brunei, Indonesia, Taiwan and Thailand. In addition to the strategic management of the business, he took personal interest in Customer Relationship Management and Aftersales operations, which resulted in a high level of clientele retention for the luxury automotive brands.
Promoted to Managing Director of the Prestige Division of Wearnes Automotive, he was instrumental in the acquisition of new brands which included Bugatti, Land Rover and McLaren. He was also the key representative of the company for the high-society clientele which included the Captains of Industry as well as esteemed members of Royal families within the region.
To nurture the passion for driving and motorsports for the entire Corporate Group, he led a team to spearhead the inaugural motorsports division. Activities included track and instructional driving days as well as distance driving weekends in Malaysia where participants had the chance to learn more about their cars and improve their driving skills whilst the company had the chance to showcase their product range and services.
When the exciting opportunity arose to develop the integrated automotive hub in Nusajaya, Iskandar Malaysia, he joined Fastrack Autosports (Iskandar) Pte Ltd to conceptualise and execute the project, in partnership with UEW Sunrise Berhad. Mr. Kan leads the joint venture company, Fastrack Iskandar Sdn Bhd as its Chief Executive Officer.
Mr. Kan has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 48, Malaysian
Independent Non-Executive Director
Ms. June Leong Lai Ling was appointed to the Board on 1 July 2022. She holds a Masters in Business Administration from Peking University in Beijing and BSc in Engineering with Management from King’s College London in United Kingdom.
Ms. June Leong currently serves as Independent Director of Thomson Medical Group Limited (“TMGL”) and is a member of the Audit and Risk Committee of TMGL. She is also currently the Chief Executive Officer of Alpha Goal International (“Alpha Goal”), a dedicated single-family office making investments around the world in a variety of asset classes including a portfolio of listed equities, hedge funds, and private equity funds.
Prior to joining Alpha Goal, Ms. June Leong was the Executive Director for China International Capital Corporation. She started her career as an Analyst with Morgan Stanley’s investment banking division in Singapore in 1995. Subsequently, she was appointed as an Executive Director of Goldman Sachs Private Wealth Management based in Hong Kong, covering Hong Kong, China and Southeast Asian clients from February 2006 to October 2008.
Ms. June Leong has no family relationship with any Director and/or major shareholder of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year under review. She has no conflict of interest with the Company. She does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 51, Malaysian
Independent Non-Executive Director
Mr. Cheah Ho Chee was appointed to the Board on 1 July 2022. He is currently the Chief Executive Officer of a boutique developer and real estate advisory firm known as ARX International where he draws on his expertise across the full property spectrum to advice on Property Development and Project Management. He is also the Chairman of SCM, an ISO 9001 accredited and Tier 1 Asset and Property Management firm.
Mr. Cheah has amassed over 25 years of professional experience across multiple countries. He has developed and managed projects in excess of RM60 billion comprising multiple Successful and Award-Winning Mixed-Use Developments, Residences, Commercial, Education Campus and Industrial developments in Malaysia and spanning across Australia, Singapore, Canada and South Africa. He also successfully managed the property development joint venture in Singapore between the sovereign wealth funds of Malaysia and Singapore.
Mr. Cheah was the Chief Operating Officer of UEM Sunrise and spearheaded the Local and International Portfolios. He was later headhunted to lead Mah Sing’s overseas expansion as Chief Executive Officer, International. Thereafter, he took the helm as the Chief Executive Officer of MRCB Land to oversee both Local and International portfolios.
Mr. Cheah holds an MBA with Distinction from the University of Sunderland in United Kingdom and BSc (Hons) Civil and Structural Engineering from the University of Iowa City in United States. He also attended Harvard Business School, ASEAN Senior Management Program.
Mr. Cheah has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year under review. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 54, Malaysian
Independent Non-Executive Director
Ms. Mazrina binti Arifin (“Ms. Mazrina”) was attached to Arthur Andersen Tax Services Sdn. Bhd. from 1995 to 1998 and was a Senior Tax Consultant prior to her leaving the firm. She was the Founder and Managing Director of Under6ers, Child Enrichment Centres, in Kuala Lumpur and Selangor from 2001 to 2009.
Ms. Mazrina was appointed as Finance Director for Springboard4 Malaysia Sdn. Bhd. and Springboard 4 Asia Ltd (Labuan) from 2010 to 2015.
Ms. Mazrina was appointed as Finance Director of the Institute for Democracy and Economic Affairs (IDEAS) Berhad, IDEAS Autism Centre (Special Project) and IDEAS Research and Policy Berhad from 2015 to present.
Ms. Mazrina was a Senior Independent Non-Executive Director of Hup Seng Industries Berhad from 2000 to 2022.
Aged 40, Singaporean
Non Independent Non-Executive Director
Dr Melvin Heng was appointed to the Board on the 26 January 2023. He is currently the Executive Director and Group Chief Executive Officer of Thomson Medical Group, Singapore. He leads and manages the Group and works actively with the Board and Management to set the overall strategic direction focused on driving business operations and growth of the Group.
Dr Heng is a physician and healthcare executive with more than 10 years of experience in hospital management, primary and specialist clinics, teleradiology, MedTech and aeromedical evacuations. Dr Heng is a medical advisor and investor in several MedTech companies such as Mesh Bio and Global Health Byte (now UNO Technologies).
From 2016 to 2018, Dr Heng served as an advisor to the Ministry of Health in the Primary Care IT sub-committee for National Electronic Health Records and GP Connect. Before joining Thomson Medical, Dr Heng was with Gleneagles Hospital where he held various leadership positions including Chief Executive Officer and Chief Operating Officer.
From 2009 to 2015, Dr Heng was a medical doctor with the National Health Service (United Kingdom) and Tan Tock Seng Hospital. After leaving the public service, Dr Heng co-founded an aeromedical evacuation company (Global Medical Concierge) and was also an equity partner at OneCare Medical, a chain of primary care clinics.
Dr Heng was awarded the Public Service Medal (COVID-19) by the Singapore Government in 2023.
Dr Heng graduated from the St George’s Hospital Medical School in London with a Bachelor of Medicine and Bachelor of Surgery (MBBS). He holds a Master of Business Administration (MBA) from the Frankfurt School of Finance and Management and has a Graduate Diploma in Occupational Medicine (GDOM) from the National University of Singapore (NUS).
Aged 49, Male, Malaysian
Independent Non-Executive Director, TMC Life Sciences Berhad
Dato’ Mohd Sheridan bin Ramli (“Dato’ Sheridan”) was appointed to the Board effective 15 July 2023.
Dato’ Sheridan specialises in the fundraising process of different and various financial instruments such as equities and debt for various corporates and institutions.
He sits on the Investment Committee panel of Urusharta Jamaah Sdn Bhd (UJSB), a wholly-owned company of the Malaysian Ministry of Finance (“MOF”). He also sits on the Investment Committee of Crewstone International, a technology fund management company which was awarded under the MOF initiative.
Dato’ Sheridan is a Board member of Bradbury Asset Management. Bradbury Asset Management Group is a fund management company in Hong Kong and Singapore which specialises in private equity and venture debt. He was the Deputy President/Chief Executive Officer of K & N Kenanga Holdings Bhd from 2006 to 2010.
He holds a Masters of Business Administration from the University of Nottingham, United Kingdom.
Aged 71, Malaysian
Non-Independent Non-Executive Chairman
Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir was appointed to the Board on 7 October 2004. He graduated with first-class honours in B.Med. Sc. (1973) and a first class honours in MBBS from Monash University, Australia in 1975 and PhD in 1982. He was awarded the FRACP (Australia) and FRCP’s from Edinburgh, Glasgow, Ireland and London and the Honorary Fellowship of the American College of Physician in June 2008 and is a Fellow of the Academy of Science Malaysia.
Professor Emeritus Dato’ Dr. Khalid started his career as a lecturer at Universiti Kebangsaan Malaysia (“UKM”) in 1982, promoted to Associate Professor in 1984, Head of Department of Medicine in 1985, Dean of the Medical Faculty and Professor in 1990. In 1997-2000, he was Director of the new Hospital Universiti Kebangsaan Malaysia (“HUKM”) with the task of building up HUKM. Upon his retirement in 2004, he was awarded the title of Professor Emeritus.
He then joined Monash University as Professor of Medicine and started the Tan Sri Jeffery Cheah Clinical School in Johor.
He was one of the pioneers of the Company and Thomson Hospitals (formerly known as Tropicana Medical Centre) and is currently the consultant Endocrinologist.
He was in the Malaysia Medical Council from 1986 to 2001, President of the Persatuan Diabetes Malaysia from 1985 to 1990, President of the Malaysia Endocrine Society from 1995 to 2001, Member of Council, International Diabetes Federation from 2001 to 2002, and Master of The Academy of Medicine of Malaysia from 2006 to 2008.
He is active in research and has published more than 310 papers in international and national peer reviewed journals. Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir was conferred The National Science Award in 1997, The Asia Pacific Nutrition Award in 1996 and The Merdeka Award in 2008, and delivered The Tunku Abdul Rahman Oration, Academy Medicine Malaysia 2010, and the Gold Medal for outstanding services to Malaysian Medical Association May 2016.
Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.